(Total Views: 621)
Posted On: 02/02/2017 5:45:22 PM
Post# of 30034
"In conclusion, AAV9-mediated hMANF gene transfer into the striatum exerts long-term neuroprotective and neuroregenerative effects on nigral DA neurons against 6-OHDA-induced neurodegeneration in parkinsonian rats. Robust and stable expression of the hMANF gene seems not to have overt side effects. Activation of the PI3K/Akt/mTOR pathway and inhibition of the ER stress may constitute mechanisms underlying MANF neuroprotection for DA cells against 6-OHDA-induced toxicity. Our study supports the development of clinical trials on MANF-based gene therapy for PD
The above is what you need to take away from the latest 2017 research article on MANF gene therapy and the Parkinsonian rat.
"Long-Term Protective Effects of AAV9-Mesencephalic Astrocyte-Derived Neurotrophic Factor Gene Transfer in Parkinsonian Rats" in Journal of Experimental Neurology.
At this point, the evidence is simply overwhelming to get MANF into the clinic for a gene therapy trial in Parkinson's disease along side CDNF.
And to top this all off, we have the recent 'Nature' article on MANF's effectiveness in treating retinal pigmentosa and other research showing its potential in treating diabetes.
The above is what you need to take away from the latest 2017 research article on MANF gene therapy and the Parkinsonian rat.
"Long-Term Protective Effects of AAV9-Mesencephalic Astrocyte-Derived Neurotrophic Factor Gene Transfer in Parkinsonian Rats" in Journal of Experimental Neurology.
At this point, the evidence is simply overwhelming to get MANF into the clinic for a gene therapy trial in Parkinson's disease along side CDNF.
And to top this all off, we have the recent 'Nature' article on MANF's effectiveness in treating retinal pigmentosa and other research showing its potential in treating diabetes.
(3)
(0)Scroll down for more posts ▼
